GLP-1 & Weight Loss

Mounjaro, Ozempic and Wegovy: A Simple Comparison

Evidence-checked Published 16 July 2026·2 min read
G&

The short version

Ranking videos treat these three like phones. Here is the comparison a good doctor actually makes, starting with the ingredient, your goal, and what the latest head-to-head trial really showed.

Somewhere online right now, a video is ranking these three medicines like phones. Winner, runner-up, loser, swipe for the verdict. It is satisfying to watch and almost useless as medicine, because the best injection is not a leaderboard position. It is whichever one suits a real person's body, history and life. Here is the comparison the way a good doctor would actually do it.

First, sort out the names. Ozempic is semaglutide. Wegovy is also semaglutide. Mounjaro is tirzepatide. Semaglutide works through one gut-hormone pathway, GLP-1. Tirzepatide works through two, GLP-1 and GIP. All three are injections in the products people argue about online, though the approved use, dose and availability shift from country to country.

Now the part rankings ignore. Your goal changes everything. For someone with type 2 diabetes, the aim might be steady blood glucose and lower long-term risk. For someone living with obesity, it might be weight loss plus improvement in linked conditions like high blood pressure, fatty liver or sleep apnoea. For some people, the honest answer is that neither is suitable, because pregnancy, certain medical histories, other medicines or side effects can take an option off the table.

The research is genuinely promising. A 2025 trial enrolled 751 adults with obesity and no diabetes, and assigned them to tirzepatide or semaglutide. At 72 weeks, average weight loss was greater with tirzepatide. Both groups had gastrointestinal side effects, especially while the dose was being raised. So tirzepatide came out ahead in that trial. Even so, a trial average is not a personal prescription. One person's side effects make a drug impossible to continue. Another has a medical reason to avoid it. A third simply cannot get it reliably month after month. Cost and the ability to show up for follow-ups weigh just as heavily as a percentage.

This is why a responsible consultation looks nothing like a ranking video. It checks blood glucose, blood pressure, kidney function, your current medicines and how you actually eat. It asks about sleep, stress and family history. The plan that comes out of it might include a medicine, and it might also include diabetes education, regular meals, a walk after dinner, and a look at the snoring nobody mentioned. The injection is one part of the care.

Comparisons that treat this as a brand contest also skip safety. Nausea, vomiting, constipation and diarrhoea can all happen. Serious or persistent symptoms need prompt advice. Anything bought without a prescription or from an unverified seller sits in a different risk category.

So before your appointment, do the one thing an algorithm cannot do for you. Write down what matters. What is this medicine meant to treat? What benefit is realistic for me? How are side effects handled, what follow-up is needed, and what happens if supply runs out? A good consultation leaves room for uncertainty and shared decisions. It never pressures you to start today.

Key message

Do not pick a medicine from a ranking video. Choose care with a qualified clinician who knows your health history.

The receipts: peer-reviewed & official sources

Every claim in this article traces back to these 2 sources.

  1. WHO GLP-1 guidance
  2. SURMOUNT-5 trial
This article explains evidence. It does not diagnose, prescribe, or replace a consultation with a qualified clinician. A registered doctor reviews articles before final publication.

Still have a question?

Ask our evidence tool. It only answers from our published, source-checked articles.

Ask the Evidence